Takeda, Affymax To Dissolve Partnership For Developing Anemia Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical plans to dissolve its partnership with Affymax and cancel joint U.S. development of their anemia drug for use with kidney dialysis after a probe failed to uncover a sometimes fatal problem.